STOCK TITAN

Ascentage Pharma Group International (AAPG) Stock News

AAPG NASDAQ

Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.

News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.

Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG) secured first-time Chinese national reimbursement coverage for lisaftoclax and renewed coverage for olverembatinib, effective January 1, 2027.

The 2026 National Reimbursement Drug List covers lisaftoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with at least one systemic therapy including a BTK inhibitor. Olverembatinib coverage continues for adults with chronic-phase chronic myeloid leukemia resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors, and adults with chronic- or accelerated-phase disease carrying the T315I mutation. All approved indications for both drugs are now covered. The company expects lisaftoclax's inclusion to improve treatment access in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.10%
Tags
none
-
Rhea-AI Summary

Ascentage Pharma (AAPG) will present clinical and preclinical findings across four drug candidates at ASH, including the first APG-5918 clinical data. The meeting runs December 12–15, 2026, in New Orleans and online. In a Phase I study, APG-5918 produced a 44.7% objective response rate among 47 efficacy-evaluable patients with relapsed/refractory T-cell lymphoma; the rate was 65.0% among 20 evaluable patients receiving 600 mg daily. No dose-limiting toxicities occurred during dose escalation.

Olverembatinib combinations produced remissions in adult and pediatric leukemia studies, including a 90.0% response rate among 10 evaluable children receiving lisaftoclax. In previously treated acute myeloid leukemia, response rates were 30% with the azacitidine triplet and 33.3% with the homoharringtonine triplet. Grade ≥3 treatment-emergent adverse events occurred in 84.8% of patients in that study. Preclinical lymphoma findings and an APG-3288 trial-in-progress abstract are also included.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.40%
Tags
none
-
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG) management will participate in two investor conferences in London on November 16 and 17, 2026.

The UBS Global Biopharma Conference presentation is scheduled for November 16, 4:40–5:10 p.m. GMT at Rosewood London. The Jefferies Global Healthcare Conference presentation is scheduled for November 17, 9:00–9:25 a.m. GMT at The Waldorf Hilton. Both events include one-on-one investor meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
Rhea-AI Summary

Ascentage Pharma (AAPG) received Breakthrough Therapy Designation in China for lisaftoclax combined with acalabrutinib for adults with previously untreated CLL/SLL.

The designation, granted by the National Medical Products Administration’s Center for Drug Evaluation, provides priority communications and development guidance. Applicants meeting relevant conditions after evaluation may seek Priority Review and conditional approval when submitting a Chinese marketing application.

CLL/SLL means chronic lymphocytic leukemia/small lymphocytic lymphoma. The combination is being evaluated as a first-line treatment in GLORA-2, one of four global registrational Phase III lisaftoclax trials underway. Lisaftoclax received Chinese approval in July 2025 for adults with CLL/SLL previously treated with at least one systemic therapy including a BTK inhibitor. The combination remains investigational and is not approved in any market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
-
Rhea-AI Summary

Ascentage Pharma (AAPG) will participate in four investor conferences in New York in September 2026, including events hosted by Citi, H.C. Wainwright, Deutsche Bank, and Bernstein. Management will join fireside chats, company presentations, and one-on-one investor meetings across multiple dates and venues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences
-
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG) reported unaudited results for the six months ended June 30, 2026, with revenue rising 29% year-over-year on a constant currency basis to US$44.5 million (RMB302.2 million), driven by a 32.6% increase in product sales to US$41.6 million. Gross profit reached RMB290.5 million (US$42.8 million).

Operating expenses expanded significantly: selling and distribution expenses grew 64.3% to US$33.4 million, research and development expenses increased 32.0% to US$102.8 million, and administrative expenses rose 19.3% to US$17.5 million. Loss for the period widened to US$120.4 million, or US$0.32 per share. Cash and bank balances were US$279.4 million, down from US$353.2 million at year-end 2025, mainly due to higher R&D spending.

The company highlighted commercial expansion of Olverembatinib and Lisaftoclax in China and progress across nine registrational Phase III trials, plus FDA and China CDE IND clearances for BTK degrader APG-3288. New Chief Business and Chief Commercial Officers were appointed, and the “B” marker was removed from its HKEX short name.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) announced that its management will participate in the Evercore ISI 2nd Annual China Biotech Summit, held on August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong. The team will join a fireside chat and hold one-on-one investor meetings.

The fireside chat is scheduled for August 18, 2026, from 7:45-8:00am Beijing Time, in Grand Ballroom 2 & 3. Investors can arrange meetings with management through their Evercore representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) corrected the timing of its upcoming disclosure, stating it will release unaudited six-month 2026 interim results and provide a corporate update at 7:00 am EDT / 7:00 pm HKT on August 19, 2026. The company will host a Mandarin investor webcast at 9:00 pm EDT on August 19 / 9:00 am HKT on August 20, 2026, and an English investor conference call and webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026, with advance registration required and an English replay available on its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings date
-
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG) appointed Dr. Faiçal Miyara as Chief Business Officer, overseeing global business development, and Jim Ziegler as Chief Commercial Officer, leading commercialization in the US and markets outside China. Both report to Chairman and CEO Dr. Dajun Yang.

The company links these hires to its advancing global registrational Phase III studies and a new phase of global expansion in hematologic malignancies. Dr. Miyara brings over 20 years of oncology business development experience at IO Biotech, Ipsen, Pfizer, ImClone Systems and Eli Lilly. Mr. Ziegler contributes more than 25 years of commercial leadership at Amgen, Gilead, Iovance Biotherapeutics and Geron.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
none
Rhea-AI Summary

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) announced that Chairman and CEO Dr. Dajun Yang has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category among 60 global pharmaceutical leaders.

According to Ascentage Pharma, Dr. Yang co-founded the company in 2009 and has led development of a small‑molecule oncology pipeline including olverembatinib, the first third‑generation BCR‑ABL tyrosine kinase inhibitor approved in China, and lisaftoclax, approved in China in July 2025 for chronic lymphocytic leukemia and small lymphocytic lymphoma. The company has commercialized these two therapies in China, is conducting multiple global registrational Phase III trials—four cleared by both the FDA and EMA—and highlights lisaftoclax as the only Bcl‑2 inhibitor in a global registrational Phase III study for higher‑risk myelodysplastic syndromes. Ascentage Pharma also notes completion of a major business development transaction and its dual primary listings in Hong Kong and on Nasdaq.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none

FAQ

What is the current stock price of Ascentage Pharma Group International (AAPG)?

Ascentage Pharma Group International (AAPG) last closed at $12.44.

What is the market cap of Ascentage Pharma Group International (AAPG)?

The market cap of Ascentage Pharma Group International (AAPG) is approximately $1.2B.